SOUTH SAN FRANCISCO, Calif., Oct. 24, 2016 -- Fluidigm Corporation (NASDAQ:FLDM) today announced it will report third quarter 2016 financial results on Thursday, November 3, 2016, after the financial markets close.
Chris Linthwaite, president and chief executive officer, and Vikram Jog, chief financial officer, will host a conference call at 2:00 p.m. PT (5:00 p.m. ET) on November 3, 2016, to discuss third quarter 2016 financial results and 2016 outlook. A press release outlining the financial results will be publicly distributed prior to the call.
Individuals interested in listening to the conference call may do so by dialing (877) 556-5248 for domestic callers, or (720) 545-0029 for international callers. Please reference Conference ID 93535469. Interested parties may access the live teleconference in the Investor Relations section of the company’s website at: http://investors.fluidigm.com/events.cfm. The link will not be active until 1:45 p.m. PT (4:45 p.m. ET) on November 3, 2016.
A telephone replay of the teleconference will be available 90 minutes after the end of the call at (855) 859-2056 (domestic toll-free), or (404) 537-3406 (international toll), Conference ID 93535469. The conference call will also be archived on the Fluidigm Investors page at: http://investors.fluidigm.com/.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for growth markets such as single-cell biology and production genomics. We sell to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/Fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm and the Fluidigm logo, are trademarks or registered trademarks of Fluidigm Corporation.
Contact: Ana Petrovic Director, Corporate Development & Investor Relations Fluidigm Corporation (650) 243-6628 (office) [email protected]


Italy Fines Apple €98.6 Million Over App Store Dominance
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
FDA Approves Mitapivat for Anemia in Thalassemia Patients
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 



